Adam Watkins
Adam Watkins is scientific leader, GSK, product development and supply, David Jack Research Centre, Ware, UK.
Articles
Risk-Based Intermediate Precision Studies for Analytical Procedure Validation
September 15th 2019Validation of analytical procedures require assessment of the impact of variations within laboratories; however, guidance to study intermediate precision has been lacking. Science and risk-based principles should be used in the design of intermediate precision studies.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: August 21st 2024 | Updated: December 31st 2024
Pharmaceutical Technology Editorial Advisory Board
Published: November 25th 2024 | Updated: December 31st 2024
Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics
Published: December 20th 2024 | Updated: December 31st 2024
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Published: February 23rd 2024 | Updated: December 31st 2024
Europa Perspectives: Helping to Navigate the Regulatory System
